In a moment of unusually high temperatures and copious rainfall, Brazil is facing a dengue outbreak like never before. This viral disease causes “severe pain and even death” in disadvantaged communities with limited healthcare.
Dengue vaccinations are hoped for in this case. Brazil’s Takeda Pharmaceuticals vaccination contract provides insufficient dosages for the population.
However, a locally-made vaccine expected in 2025 is hoped for. In clinical trials, Butantan-DV is the most effective vaccination since it protects against dengue virus serotypes and may provide long-term immunity.
Traditional vaccines require two doses, whereas Butantan-DV is a single dose, making it more convenient and accessible. Second, it will be cheaper than other alternatives, increasing its access to the poor.
Dengue control still relies on vaccination, but new mosquito control strategies are being developed. Wolbachia-infected mosquito release and sterilised male mosquitoes are helping reduce dengue transmission.
Despite these advances, challenges remain to expand vaccination programs and ensure innovative vaccine safety and efficacy. Biotechnology pest control requires continual study and monitoring to identify side effects and adjust control techniques. Brazil keeps fighting dengue due to new technologies and vaccine development. Therefore, efforts should be made with diligence, and there is hope for better days.
